Archive: 03/07/2014

Express Scripts cuts payments for customized drugs

The nation's largest pharmacy benefit manager, Express Scripts, is dramatically scaling back its coverage of compounded medications, saying most of the custom-mixed medicines are ineffective or overpriced.

Beleodaq approved for aggressive non-hodgkin lymphoma

(HealthDay)—Beleodaq (belinostat) has been approved by the U.S. Food and Drug Administration to treat peripheral T-Cell lymphoma (PTCL), a rare and aggressive form of non-Hodgkin lymphoma (cancer of the lymph nodes).

page 2 from 8